Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia states the
median survival rate nearly doubles combining Inotuzumab with chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Median Survival Rate Nearly Doubles Combining Inotuzumab with Chemotherapy
